FLT3 and acute myeloid leukemia: Among these, the second-generation FLT3 inhibitors quizartinib and gilteritinib as single agents improved marrow remission rates and OS compared with traditional salvage chemotherapies (investigator’s choice of high-intensity therapies such as fludarabine–Ara-C–granulocyte colony-stimulating factor–idarubicin or mitoxantrone-etoposide-cytarabine, or low-intensity therapies such as HMAs or LDAC) in relapsed/refractory FLT3-mutated AML patients57–60.